Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stempeucel in Critical Limb Ischemia
NCT00883870Phase 2Completed
- Sponsor
- Stempeutics Research
- Start
- Apr 2009
- Primary completion
- Feb 2010
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Stempeucel in critical limb ischemia (CLI) (2 arms), sponsored by Stempeutics Research. Primary endpoint: Adverse Events and Symptomatic Relief at 6 months. Started Apr 2009; status: completed.
02
Drugs
Stempeucel
03
Conditions
critical limb ischemia (CLI)
Beyond the preview
Go deeper on NCT00883870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00883870.